NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
Collaboration Partners LinaThera, NUCLIDIUM, Medical Valley Center Forchheim, Klinikum Bayreuth und Erlangen University Hospital Receive Funding from Oberfrankenstiftung for the Production and Clinical Development of Radionuclide Therapies
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics
